Difference between revisions of "Cancer drugs"
Jump to navigation
Jump to search
(create) |
(No difference)
|
Revision as of 02:45, 15 August 2011
This article covers cancer drugs from a pathology perspective.
Drugs in a table
| Non-proprietary name | Trade name | Cost | Indication | Notes |
|---|---|---|---|---|
| cetuximab | Erbitux | 5267 Euros/month[1] | stomach cancer, head & neck cancer | notes? |
| trastuzumab | Herceptin | 3345 Euros/month[1] | breast cancer, stomach cancer | notes? |
| non-proprietary name | Iressa | 3496 Euros/month[1] | Lung cancer | notes? |
| panitumumab | Vectibix | 3537 Euros/month[1] | indication | notes? |
| non-proprietary name | Faslodex | 719 Euros/month[1] | breast cancer | notes? |
| non-proprietary name | Femara | 4189 Euros/month[1] | indication | notes? |
| non-proprietary name | Glivec | 4189 Euros/month[1] | ALL, CML | notes? |
| non-proprietary name | Sprycel | 7513 Euros/month[1] | ALL, CML | notes? |
| non-proprietary name | Tasigna | 5685 Euros/month[1] | CML | notes? |
| non-proprietary name | Tyverb | 3441 Euros/month[1] | breast cancer | notes? |